z-logo
open-access-imgOpen Access
Management of co-infection with HIV and TB
Author(s) -
Robert Colebunders
Publication year - 2002
Publication title -
bmj
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.831
H-Index - 429
ISSN - 0959-8138
DOI - 10.1136/bmj.324.7341.802
Subject(s) - tuberculosis , medicine , human immunodeficiency virus (hiv) , antiretroviral therapy , developing country , active tuberculosis , isoniazid , mycobacterium tuberculosis , cause of death , immunology , intensive care medicine , viral load , disease , economic growth , pathology , economics
About a third of the 36 million people living with HIV worldwide are co-infected with mycobacterium tuberculosis; 70% of those co-infected live in sub-Saharan Africa.1 In developing countries half of people with HIV infection will develop active tuberculosis; in some countries in sub-Saharan Africa more than 70% of patients with active tuberculosis are also HIV seropositive.1 Tuberculosis is the leading cause of death among people with HIV infection, accounting for a third of deaths due to AIDS world wide.2 The introduction of highly active antiretroviral therapy has decreased death and opportunistic infections by 60% to 90% among people living with HIV in affluent countries,3 but in developing countries highly active antiretroviral therapy is available to a tiny minority of those who need it. Today there is a shocking inequality worldwide in the prognosis of HIV and tuberculosis co-infection, and it depends on whether patients or their country have access to highly active antiretroviral therapy.Many regimens have been proposed for treating latent tuberculosis infection; the preferred option is still isoniazid, recommended for nine months.4 In settings …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom